Karyopharm Therapeutics PEG Ratio

Karyopharm Therapeutics (KPTI) currently reports a PEG ratio of 10.95. That is below the Healthcare sector average of 11.05. Use the charts on this page to explore Karyopharm Therapeutics's PEG ratio history and peer comparisons.

Karyopharm Therapeutics's PEG ratio of 10.95 is lower than the Healthcare sector average of 11.05. That is roughly 1.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Karyopharm Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 10.95, KPTI can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 10.95, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.05. From there, open related valuation or income-statement pages for Karyopharm Therapeutics, and consider following KPTI for alerts when major investors trade the stock.

Karyopharm Therapeutics is classified in the Healthcare sector. On PEG ratio, it currently shows 10.95 versus a sector average near 11.05. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KPTI with unrelated industries.